Профази (Chorionic Gonadotropin) is commonly used to provide supportive hormonal signaling in situations related to reproductive and endocrine function, with applications across several key therapeutic domains.

Ovulation Induction and Fertility Treatment Support

This medication is commonly used when female infertility is rooted in ovulatory dysfunction—the failure of the ovary to release a mature egg. By providing a hormonal signal, Профази is considered relevant for easing the symptoms related to systemic imbalance and triggering the final stage of egg maturation and release. This supportive action contributes to the possibility of conception during controlled fertility cycles.

Managing Hypogonadism and Sustaining Male Fertility

Профази is applied in clinical settings that involve organ-specific functional stress in adult men with secondary hypogonadotropic hypogonadism. Its use may assist with managing symptoms related to systemic imbalance by providing supportive relief for endogenous hormone production. This is considered relevant for patients seeking to manage hypogonadal symptoms while supporting their reproductive health.

Quick Fact: Relief for Symptoms Linked to Endocrine Imbalance

Профази is commonly used when hormone levels are characterized by periods of heightened physiological stress or when a specific timing signal is absent. Its use helps address symptom clusters that may become disruptive, such as the failure of final egg maturation or insufficient androgen support, assisting with maintaining functional stability.

This section explains who is eligible to use Профази (Chorionic Gonadotropin) and who must not use it, strictly based on official government regulatory documents.

Populations That Must Not Use Профази (Contraindications)

The medicine is formally contraindicated (prohibited) for use in individuals with the following conditions, as stated in authoritative labeling:

• Known Hypersensitivity: A prior allergic reaction to Chorionic Gonadotropin (hCG) or any of the inactive ingredients (excipients) in the formulation.
• Androgen-Dependent Malignancies: The presence or suspicion of tumors that are sensitive to hormones, such as prostatic carcinoma or other specified hormone-dependent tumors in the breast, ovary, or uterus.
• Precocious Puberty: A condition that causes early onset of puberty.
• Undetermined Abnormal Bleeding: Women with abnormal uterine or vaginal bleeding when the cause has not been definitively diagnosed.
• Current Pregnancy: Use is strictly contraindicated in pregnancy as the drug may cause fetal harm.

Eligibility-Related Restrictions

• Lactation (Breastfeeding): Use is generally not recommended during breastfeeding, as the effects on the nursing infant are unknown.
• Age Considerations: While the drug is used for specific conditions in children (e.g., cryptorchidism), it is contraindicated in precocious puberty for certain indications. The safety and effectiveness in children under a specified age may also not be established, and signs of early puberty should lead to discontinuation of therapy.

Interactions with other medicines and products

Official regulatory documents for Профази (Chorionic Gonadotropin, hCG), an injectable glycoprotein hormone, indicate a minimal interaction profile. This is primarily due to the drug’s chemical structure and its metabolism by general proteolysis, rather than by the specialized Cytochrome P450 (CYP) enzyme system typically involved in drug-drug interactions.

Regulatory authorities do not list specific restrictions or warnings regarding interactions with other substances.

Interaction Category	Regulatory Status (Official Documentation)
Contraindicated Combinations	None documented. No medicinal products are formally prohibited based solely on interaction risk.
Pharmacokinetic (PK) Interactions	None documented. The drug is not a substrate, inhibitor, or inducer of the CYP enzyme system; no changes in exposure (AUC/Cmax) or clearance by co-administered medicines are officially identified.
Pharmacodynamic (PD) Interactions	None documented. No additive or synergistic effects with co-administered medicines are explicitly described in regulatory labels.
Food, Alcohol, or Supplements	None documented. Due to the parenteral administration route, no official restrictions or mandatory cautions regarding co-use are specified.

In summary, official prescribing information confirms that Профази is not associated with any clinically significant drug-drug, drug-food, or drug-substance interactions documented across the major categories of pharmacokinetic and pharmacodynamic effect.

How Профази Works

Профази acts by functionally mimicking the body's natural Luteinizing Hormone (LH) to influence defined molecular pathways at the cellular level. Its mechanism is centered on activating specific hormonal pathways to drive the synthesis of essential steroid hormones.

---

Sustained Agonism at the LHCGR

The core action of Профази (hCG) begins as it acts as a strong functional agonist on the Luteinizing Hormone/Choriogonadotropin Receptor (LHCGR) found on ovarian and testicular cells. The drug's structure facilitates a prolonged, tonic activation of this receptor compared to endogenous LH, contributing to signal sustainability necessary for metabolic signaling.

Driving the Steroidogenic Cascade

Activation of the LHCGR triggers the Gαs protein and subsequent stimulation of the cAMP/PKA signaling pathway inside the cell. This cascade potently activates the molecular machinery responsible for converting cholesterol into hormones, including the crucial Steroidogenic Acute Regulatory protein (StAR), which governs the rate-limiting step of steroid synthesis.

Upregulation of Gonadal Steroid Production

This sustained cellular signaling results in a significant increase in the synthesis and output of gonadal steroid hormones, namely progesterone and testosterone. The resulting surge in steroid levels produces the necessary physiological environment for subsequent reproductive sequences such as final oocyte maturation or the sustained local androgen levels required for spermatogenesis.

Profasi (chorionic gonadotropin) is a prescription medication administered by injection, typically intramuscularly or subcutaneously. It is crucial to use this medicine exactly as prescribed by your healthcare provider, following the detailed instructions for dosage, timing, and injection technique.

Administration and Preparation

• Method: Profasi is generally supplied as a lyophilized powder requiring reconstitution with a provided sterile diluent. Once mixed, the solution must be clear and colorless. Your doctor, nurse, or pharmacist will provide specific training on the proper mixing and injection procedure for home use.
• Injection: The injection is typically given either into a muscle (intramuscular) or beneath the skin (subcutaneous). Do not attempt to self-inject unless you have been fully trained and are comfortable with the technique, including the safe disposal of used needles in a puncture-proof container.

Important Considerations

Area of Concern	Patient Instruction
Dosing Schedule	Follow the prescribed schedule precisely; missing a dose, particularly in fertility treatments, can compromise the therapeutic outcome.
Monitoring	Regular medical monitoring is necessary during treatment. This may involve blood tests (hormone levels) and ultrasound examinations, especially for women undergoing ovulation induction, to check for potential complications such as Ovarian Hyperstimulation Syndrome (OHSS).
Storage	Unmixed powder should be stored as directed by the manufacturer. After reconstitution, the mixture must be kept refrigerated and used or discarded within the time specified by your healthcare provider, often within 30 days.

If you have any questions or concerns about the administration or a missed dose, contact your healthcare team immediately. Never adjust your dosage or administration schedule without consulting your doctor.

Research Evidence / Overview of Studies for Профази (Chorionic Gonadotropin)

---

Evidence for Use in Ovulation Induction

Research examined the agent in women with infertility related to ovulatory dysfunction, where the ovary fails to release an egg. This area of study is supported primarily by high-quality Randomized Controlled Trials (RCTs) and systematic reviews. These studies monitored key hormonal and reproductive endpoints, including the rate of confirmed ovulation and the final clinical pregnancy rate recorded during the study period.

In these research scenarios, the agent was studied for its role as a hormonal trigger—a signal administered after the ovarian follicles have been stimulated using other medications. Findings describe patterns observed in the studies related to outcomes describing episodic or acute changes within the reproductive system. The evidence contributes to the broader evidence landscape by providing context on how a final hormonal surge research describes the agent's role within a controlled fertility regimen.

---

Evidence for Use in Male Hypogonadism Management

Research has explored the use of this agent in adult males diagnosed with secondary hypogonadotropic hypogonadism, a condition characterized by hormonal imbalance. The research base includes systematic reviews, observational cohorts, and some comparative studies. These studies explored outcomes related to systemic or functional imbalance, such as shifts in testosterone levels and the induction and concentration of sperm production (spermatogenesis).

Findings indicate patterns related to measurable changes in specific hormonal biomarkers over the course of treatment. Due to the nature of the biological process, research often involved defined time intervals requiring intermediate-to-long-term observation, sometimes spanning up to 18 to 24 months, to fully document the reproductive outcome.

---

Research Gaps and Areas of Uncertainty

The available evidence highlights what is known — and what is still uncertain about Профази. A consistent limitation is that comparative evidence is lacking in high-quality head-to-head trials against newer therapeutic options across its indications. For all uses, sample sizes were modest in many of the defining studies, and evidence quality varies across studies. There is a general need for more research that explores short-term symptom changes and physical outcomes over extended follow-up durations to characterize the long-term clinical picture for individuals after completing therapy.

Key Studies & References

1. Hormonal cryptorchidism therapy: systematic review with metanalysis of randomized clinical trials

Common questions about Профази (FAQ)

Q: What steps should I take if I forget to give myself a dose?

Official regulatory documents emphasize the importance of following the prescribed schedule precisely. If a dose is missed, it is recommended to contact your healthcare provider, such as your doctor or pharmacist. A healthcare team member can provide guidance on managing a missed dose and adjusting the treatment schedule.

Q: What are the ingredients in the Profasi injection?

The active ingredient in the injection is Chorionic Gonadotropin. According to the product information, the final mixed solution also contains inactive ingredients, or excipients, which may include substances like mannitol and sodium phosphate to ensure the drug's stability. The diluent provided for mixing often contains bacteriostatic water.

Q: Does Profasi need to be administered at a specific time of day?

For certain treatment regimens, such as those for ovulation induction, the timing of the administration is considered critical. Official prescribing information states that the dose may need to be administered at a specific time point relative to the patient's other fertility medications.

Q: Can Profasi be used in children?

Yes, regulatory documents indicate that Chorionic Gonadotropin is approved for use in specific pediatric male patients. This is typically for the treatment of prepubertal cryptorchidism (undescended testicle). The official label indicates that the safety and effectiveness for other uses or in children below a specified age (such as under age four) may not be established.

Q: Is Profasi a natural or synthetic hormone?

The active ingredient, Chorionic Gonadotropin, is classified as a water-soluble polypeptide hormone. Official product information confirms that it is sourced as a highly purified substance typically extracted from the urine of pregnant women, meaning it is of natural origin.

The required storage conditions for Профази (Chorionic Gonadotropin) vary based on its form.

Official Storage Requirements

Product Form	Required Storage Condition
Unreconstituted Powder	Controlled Room Temperature (20 C to 25 C) in the original carton.
Reconstituted Solution	Refrigerated (2 C to 8 C).

The powder must be protected from light and moisture. The liquid solution must not be frozen as this compromises the medication's stability. After reconstitution, the solution has a defined shelf-life, typically 30 to 60 days when refrigerated, after which it must be discarded.

Handling and Disposal

Профази must be kept out of the sight and reach of children.

Used needles and syringes must be immediately placed in an approved, puncture-proof sharps container. Unused or expired medication must be disposed of according to local regulatory and environmental guidelines for pharmaceutical waste.